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Introduction
Since several primary tumours, such as those of breast, lung and prostate, are known to build metastases into osseous tissue, skeletal imaging and bone pain palliation represent major tasks in nuclear medicine. In clinical routine, a variety of radioactively labelled polyphosphonates (MDP, DPD , EDTMP, …) provide convenient and effective means to monitor disease progression or improve life quality of the patients, depending on the nature of the chosen radionuclide (Subramanian et al., 1975) .
Either way, the minimisation of both the radiation burden to the patient and interfering signals in the scintigraphic image requires specific skeletal localisation of the radiopharmaceuticals (Billinghurst, 1982) . Although bone seekers have been used for more than 30 years in nuclear medicine, the underlying mechanism involved in their accumulation in osseous tissue is still under discussion (Francis et al., 1980; Kanishi, 1993; Okamoto, 1995) . Hypotheses regarding these mechanisms range from adsorption onto the mineral or organic phase of bone to incorporation into the mineralisation processes with disputed contribution of bone cells.
The absence of secured knowledge rules out the possibility of modern rational drug design, including the analysis of structure-activity relationships, in the development of novel bone seeking agents. Hence, the first step in the preclinical evaluation of any new bone seeker involves biodistribution and efficacy studies in laboratory animals. The demand of laboratory animals goes even further: the European pharmacopoeia specifies (European Pharmacopoeia, 2005 ) that as part of quality control each charge of the officinal polyphosphonate has to be tested regarding its biodistribution in 3 rats prior to release. 
Preparation of human cortical bone powder (Co)
The preparation followed methods reported elsewhere (Kluger et al., 2003) . Briefly, bone specimens were excised from donors, washed, freeze-dried and sterilised. Afterwards, these allografts were processed into a fine powder by milling. Measurements revealed a particle size in a comparable range to the commercially available HA.
Binding experiments
To a vial containing 3 mg of HA or Co 3 ml of HBSS were added and the vial was swayed at 37°C for 24 h. Radioactively labelled polyphosphonate (content of ligand: 0.3 µmol, based on commercially available radiolabelling kits) Mitterhauser et al., 2005; Toegel et al., 2006a; Mitterhauser et al., 2007) or 25 MBq [
18 F]-fluoride were added. Then the tube was returned to the water bath (120 min, 37°C) and vortexed every 15 min and before extraction.
Binding measurement
After 120 minutes of incubation an aliquot of 50 µl of this suspension was added to 2 ml of physiological saline. Out of this dilution, three aliquots of 50 µl were taken and placed in tubes for the gamma-counter. The rest of the dilution was filtered through a Millex-SG single use filter unit, and three aliquots of 50 µl were taken from the filtrate and placed in tubes. The radioactivity of the six tubes was measured in the gamma-counter, and the percentage of irreversibly bound radiolabelled PP was calculated as percent binding.
Filter experiments and filter correction
Filter experiments were performed to control for the amount of unspecific radioactivity retained during filtration. 18 F]-fluoride, data acquisition was started. The dynamic image data (energy window: 250-750 keV; timing window: 6 ns) were sorted into 3-dimensional sinograms (frames: 7x1 min, 4x2 min, 3x5 min, 3x10 min, 8x15 min). All sinograms were Fourier transformed into 2D sinograms prior to reconstruction. Dynamic images were reconstructed using 2D filtered back projection with a ramp filter cut-off at the Nyquist frequency. Transmission scans using a Co-57 point source were performed for 10 minutes. Emission data were corrected for detector efficiency, random coincidences, dead time, isotope decay and attenuation. The PET image volume (128x128x95) was reconstructed with a zoom of 6 and had a voxel size of 0.32x0.32x0.8mm 3 .
Biodistribution experiments
After microPET scans all animals were killed by cervical dislocation, organs (femurs, tail, liver, kidneys) were dissected within a few minutes, weighed and subjected to gamma-counting. The percentage of injected dose per gram tissue (%ID/g) was calculated using two calibration curves (high and low activity) with known activities and decay corrected for the injection time.
Statistics
Statistical analyses were performed using the Microsoft Excel integrated analysis tool. Hypothesis tests among two data sets were made by comparison of two means from independent (unpaired) samples (t-test). A value of p<0.05 was considered significant. Descriptive statistical analyses were performed using mean values and standard deviations.
Results
Binding experiments
Results of the binding experiments on HA are presented in It is evident that uptake depends on the structure of the polyphosphonate ligand, the radionuclide used for radiolabelling and the nature and amount of carrier. 
Biodistribution experiments
Results are presented in Table 3 . It is evident that accumulation of [ 18 F]-fluoride in the femur was significantly higher (p<0.01) as compared to that of [ 68 Ga]-EDTMP (both SUV (standardised uptake value) and %ID/g), whereas no significant difference for all the other organs was observed.
Discussion
Although the exact mechanisms of bone uptake are discussed controversially, the involvement of the inorganic bone compartment in this process seems to be undisputed. In autoradiographic analyses of foetal calvarias, Kanishi (1993) found high uptake in the area of the osteoblast-like cells, whereas no uptake was found in osteoblast-like cells themselves in vitro. Francis et al. described the involvement of inorganic structures in the drastically increased uptake in osteoblastic bone pathologies (Francis and Fogelman, 1987; Francis et al., 1980) . In contrast, it is known that areas of osteoclastic activity show reduced uptake. Since uptake of bone seekers is presumably restricted to the mineral phase of bone, we developed an in vitro model for the evaluation of this bone seeker -matrix interaction Mitterhauser et al., 2005) . Based on our studies and an in-depth survey of the results, we developed the hypothesis that our model may either reduce or even replace animal experiments in the field of radioactive bone seekers. Up to the present, these animal experiments are demanded for quality control procedures (European Pharmacopoeia, 2005) and are supposed to be mandatory during tracer development. The present manuscript was designed to suggest our model as an alternative to animal experiments for the prediction of in vivo binding characteristics. In order to substantiate this hypothesis, the following correlations are presented:
(1) The model reflects hydroxyapatite binding characteristics in mineralising osteoblast cell culture. In an experimental set up, where osteoblasts from mouse calvariae were cultured under forced mineralising conditions, we quantified binding of several bone seekers (Toegel et al., 2006b ). We found a good correlation between the binding values determined in our in vitro model and those observed in the cultures. Since we could verify that binding took place solely on hydroxyapatite and not on the osteoblasts themselves, this comparison revealed that our model could reflect and replace studies on these primary animal cells.
(2) The model reflects binding characteristics on human ex vivo bone allografts.
Comparing Table 1 and Table 2 , it is evident that uptake rankings of all n.c.a. formulations based on EDTMP are in the same order Ga < Tc < Re < In < Y < Sm. both matrices (Mitterhauser et al., 2005; Toegel et al., 2006a; Toegel et al., 2007) . These facts strengthen the use of hydroxyapatite as a surrogate for human bone allografts. (Füger et al., 2004; Mitterhauser et al., 2001) . We found uptake in the order: n.c.a. 
Conclusion
The present report describes the use of an in vitro model for bone seekers based on simple binding to hydroxyapatite and its application for evaluating bone binding characteristics. On the basis of our findings we feel confident that this model could serve as a convenient alternative to animal experiments for the comparative evaluation of bone seekers. It could even be a basis for the development of a future pharmacopoeia-listed method allowing both the officinal quality control of bone seekers and a more respectful approach to animals.
